Department of Dermatology, Saudi German Hospital and Clinic, Opposite Burj Al Arab, Dubai, UAE.
Dis Markers. 2021 Dec 30;2021:6238317. doi: 10.1155/2021/6238317. eCollection 2021.
Melanoma, which is an aggressive skin cancer, is currently the fifth and seventh most common cancer in men and women, respectively. The American Cancer Society reported that approximately 106,110 new cases of melanoma were diagnosed in the United States in 2021, with 7,180 people dying from the disease. This information could facilitate the early detection of possible metastatic lesions and the development of novel therapeutic techniques for melanoma. Additionally, early detection of malignant melanoma remains an objective of melanoma research. Recently, melanoma treatment has substantially improved, given the availability of targeted treatments and immunotherapy. These developments have highlighted the significance of identifying biomarkers for prognosis and predicting therapy response. Biomarkers included tissue protein expression, circulating DNA detection, and genetic alterations in cancer cells. Improved diagnostic and prognostic biomarkers are becoming increasingly relevant in melanoma treatment, with the development of newer and more targeted treatments. Here, the author discusses the aspects of biomarkers in the real-time management of patients with melanoma.
黑色素瘤是一种侵袭性皮肤癌，目前是男性和女性中第五和第七常见的癌症。美国癌症协会报告称，2021 年在美国诊断出约 106110 例黑色素瘤新病例，有 7180 人死于该疾病。这一信息可以促进对可能发生的转移病灶的早期检测，并开发治疗黑色素瘤的新治疗技术。此外，早期发现恶性黑色素瘤仍然是黑色素瘤研究的目标。最近，由于靶向治疗和免疫疗法的出现，黑色素瘤的治疗有了显著改善。这些发展突出表明了确定用于预后和预测治疗反应的生物标志物的重要性。生物标志物包括组织蛋白表达、循环 DNA 检测和癌细胞中的遗传改变。随着更新和更具针对性的治疗方法的出现，改进的诊断和预后生物标志物在黑色素瘤治疗中变得越来越重要。在这里，作者讨论了生物标志物在黑色素瘤患者实时管理中的各个方面。
